Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05641064
Other study ID # 78Z11053
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 22, 2022
Est. completion date December 31, 2025

Study information

Verified date May 2023
Source University Hospital Dubrava
Contact Zrinka Safaric Oremus, MD
Phone +38598242538
Email zsafarico@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aim of this randomized prospective study is to investigate the immunomodulatory effects of dexmedetomidine on outcomes in patients with isolated aortic stenosis after surgical aortic valve replacement.


Description:

Study will investigate effects of two different doses of dexmedetomidine on concentrations of tumor necrosis factor-α and interleukin-6, on inflammatory parameters (C reactive protein and procalcitonin) and inflammatory complications, renal function, postoperative delirium, anaesthetic and analgetic consumption and compare it to control group. It should provide a better understanding of dexmedetomidine effect on decrease of inflammatory response in patients undergoing cardiac surgery. Short-term infusion of dexmedetomidine could reduce inflammatory postoperative complications, contribute to improvement of perioperative renal function and occurrence of postoperative delirium, supporting recovery and shortening hospital stay.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2025
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - isolated aortic stenosis adult patients with written consent Exclusion Criteria: - BMI <30kg/m2 - 1st, 2nd and 3rd degree AV block - bradycardia HR<50/min upon arrival to operating theatre - neurological disorders (Parkinson's disease, Myasthenia gravis, multiple sclerosis, brain tumors in anamnesis) - recent use of psychoactive drugs - alcohol and illicit drug addiction - diabetes type I with complications - patients who develop hypotension after initiation of dexmedetomidine infusion requiring vasoconstriction therapy - patients receiving corticosteroids in perioperative period - patients with known allergy to dexmedetomidine

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Continuous infusion of saline starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
Dexmedetomidine 0.5mcg/kg/h
Continuous infusion of dexmedetomidine in 0.5mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
Dexmedetomidine 1 mcg/kg/h
Continuous infusion of dexmedetomidine in 1mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion

Locations

Country Name City State
Croatia University hospital Dubrava Zagreb

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Dubrava

Country where clinical trial is conducted

Croatia, 

References & Publications (3)

Bulow NM, Colpo E, Pereira RP, Correa EF, Waczuk EP, Duarte MF, Rocha JB. Dexmedetomidine decreases the inflammatory response to myocardial surgery under mini-cardiopulmonary bypass. Braz J Med Biol Res. 2016;49(4):e4646. doi: 10.1590/1414-431X20154646. Epub 2016 Feb 23. — View Citation

Lee JM, Han HJ, Choi WK, Yoo S, Baek S, Lee J. Immunomodulatory effects of intraoperative dexmedetomidine on T helper 1, T helper 2, T helper 17 and regulatory T cells cytokine levels and their balance: a prospective, randomised, double-blind, dose-response clinical study. BMC Anesthesiol. 2018 Nov 8;18(1):164. doi: 10.1186/s12871-018-0625-2. — View Citation

Ma Y, Yu XY, Wang Y. Dose-related effects of dexmedetomidine on immunomodulation and mortality to septic shock in rats. World J Emerg Med. 2018;9(1):56-63. doi: 10.5847/wjem.j.1920-8642.2018.01.009. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary interleukin 6 Concentration of IL-6 24 hours preoperatively (T0), before CPB initiation (T1), 5 hours post CPB (T2) and 12 hours post CPB (T3) 24 hours preoperatively up to 12 hours post CPB
Primary tumor necrosis factor alpha Concentration of TNF-alpha 24 hours preoperatively (T0), before CPB initiation (T1), 5 hours post CPB (T2) and 12 hours post CPB (T3) 24 hours preoperatively up to 12 hours post CPB
Secondary Inflammatory marker concentration during hospital stay Determination of concentration of CRP and procalcitonin during hospital stay From recruitment date up to 30 days postoperatively
Secondary Infection rate Determining incidence of wound infection, pneumonia, urinary infection and sepsis during hospital stay From recruitment date up to 30 days postoperatively
Secondary Renal function - diuresis Determining parameters of renal function: Daily 24-hour urine output in ml From recruitment date up to 10 days postoperatively
Secondary Renal function - diuretic consumption Determining parameters of renal function: diuretic consumption From recruitment date up to 10 days postoperatively
Secondary Renal function - GFR Determining parameters of renal function: glomerular filtration rate From recruitment date up to 10 days postoperatively
Secondary Renal function - creatinine Determining parameters of renal function: creatinine concentration From recruitment date up to 10 days postoperatively
Secondary Renal function - urea Determining parameters of renal function: urea concentration From recruitment date up to 10 days postoperatively
Secondary Postoperative delirium Determining incidence of postoperative delirium using Confusion Assessment Method questionaire From recruitment date up to 30 days postoperatively
Secondary Analgesic and anesthetic consumption Determining intraoperative anesthetic consumption (midazolam, sufentanil, propofol and sevoflurane) and postoperative analgesic use From recruitment date up to 10 days postoperatively
See also
  Status Clinical Trial Phase
Completed NCT03186339 - Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Terminated NCT02854319 - REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System N/A
Recruiting NCT05601453 - The ReTAVI Prospective Observational Registry
Withdrawn NCT05481814 - CPX in Paradoxical Low Flow Aortic Stenosis
Completed NCT02241109 - Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity N/A
Completed NCT01700439 - Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve N/A
Recruiting NCT04429035 - SLOW-Slower Progress of caLcificatiOn With Vitamin K2 N/A
Completed NCT04103931 - Impact of a Patient Decision Aid for Treatment of Aortic Stenosis N/A
Completed NCT03950440 - Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
Active, not recruiting NCT02661451 - Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) N/A
Completed NCT02847546 - Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation N/A
Completed NCT02758964 - Evaluation of Cerebral Thrombembolism After TAVR
Completed NCT02792452 - Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
Not yet recruiting NCT02541877 - Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve Phase 3
Not yet recruiting NCT02536703 - Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population Phase 3
Not yet recruiting NCT02221921 - Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI N/A
Completed NCT02249000 - BIOVALVE - I / II Clincial Investigation N/A
Active, not recruiting NCT02080299 - Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation Phase 2
Terminated NCT01939678 - Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease